Application 761336
- Type
- BLA
- Sponsor
- ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761336 | Anktiva | nogapendekin alfa inbakicept-pmln | 351(a) | Rx | 2026-09-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | ANKTIVA | nogapendekin alfa inbakicept-pmln | SOLUTION;INTRAVESICAL | 400mcg/0.4 mL | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ANKTIVA | NOGAPENDEKIN ALFA INBAKICEPT-PMLN | Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc. | eae31db8-3e7a-d9e0-708d-74419d1b50ff | 2025-06-24 | Warnings, Adverse reactions | BLA761336 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.